| Name | Title | Contact Details |
|---|---|---|
Ling Zeng |
Chief Legal and Administrative Officer | Profile |
Jeffrey Kopacz |
Vice President, Intellectual Property | Profile |
CENTOGENE - transforming genetic data into medical decisions. We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the worlds largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.
Drug Development Resources is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mérieux NutriSciences is a service company headquartered in Chicago.
Comp-U-charge is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spaltudaq Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.